Business context and reporting period
SenesTech, Inc. (Nasdaq: SNES) filed this Form 10-K for the fiscal year ended December 31, 2023. The company develops and commercializes rat fertility-control products: ContraPest, an EPA-registered liquid bait, and Evolve, a soft bait launched in November 2023 that qualifies for the federal FIFRA Section 25(b) minimum-risk exemption. At year-end, Evolve was authorized for sale in 30 states.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $1.193 million | $1.019 million |
| Gross profit / margin | $539,000 / 45.2% | $464,000 / 45.5% |
| Operating expenses | $8.271 million | $10.138 million |
| Operating loss | $7.732 million | $9.674 million |
| Net loss | $7.710 million | $9.695 million |
| Net cash used in operating activities | $7.566 million | $8.577 million |
Revenue increased 17%, with growth in agribusiness, commercial and distributor sales; e-commerce declined 10%. Gross margin was nearly flat year over year. Lower R&D and selling, general and administrative expenses contributed to the narrower net loss.
At December 31, 2023, cash and cash equivalents were $5.395 million, current assets $6.673 million, current liabilities $786,000, total liabilities $942,000, and stockholders’ equity $6.351 million. Notes payable totaled $189,000, including $33,000 current, at a stated 9.1% annual interest rate. Operating cash outflow was partly offset by $8.335 million in financing cash flow, including $5.407 million net proceeds from common-stock issuance and $2.831 million from warrant exercises. The company reported an accumulated deficit of $129.9 million.
Material changes, outlook and risks
- Management estimated year-end cash, together with anticipated revenue, would fund current operations for at least nine months from December 31, 2023. It warned that lower-than-expected revenue or margins, or higher expenses, could require financing sooner. The auditor’s report expresses substantial doubt about the company’s ability to continue as a going concern without additional capital.
- In November 2023, the company completed a 1-for-12 reverse stock split and a financing with approximately $5.0 million gross proceeds before fees. The offering included substantial warrants; 7.776 million warrants remained outstanding at year-end. As of February 20, 2024, 5,144,632 common shares were outstanding.
- Management expects continued operating losses and additional financing needs; the filing provides no quantified revenue or earnings guidance. The company intends to focus resources on commercialization of ContraPest and Evolve and expected to introduce another product during 2024.
- Key commercial risks include limited product sales to date, uncertain customer adoption, and the need to build effective sales and distribution. ContraPest registrations and label restrictions, ongoing testing requirements, and Evolve’s state-by-state authorization may constrain market access. Management reported production capacity adequate for anticipated demand through 2024, but manufacturing is at one site and triptolide is sourced from limited suppliers, including China.
- Additional risks include Nasdaq minimum-bid-price compliance, potential dilution and warrant-related financing constraints, and regulatory changes affecting rodenticides or ContraPest. A former general counsel’s lawsuit was settled for $185,000 in November 2023. The filing also describes potential SEC action or purchaser rescission claims related to an alleged resale of approximately 175,000 shares before a registration statement became effective; the outcome is uncertain.
- The financial statements are audited. Management concluded internal control over financial reporting was effective, but the auditor did not attest to that assessment because of the applicable smaller-reporting-company transition rules.
Important facts for investors to verify
- Cash runway and financing needs against actual quarterly operating cash burn and revenue progress.
- Sales growth, gross margins, and adoption of ContraPest and the newly launched Evolve by channel and customer segment.
- Remaining warrant terms, potential share issuance, dilution, and the company’s ability to raise capital on acceptable terms.
- Nasdaq listing compliance status and any subsequent financing, reverse split, or share-count changes.
- Regulatory status, required testing, state availability, and any developments in the disclosed SEC-related exposure.